Almac Diagnostic Services has announced a significant investment in a new Illumina NovaSeq 6000 sequencer which will benefit Biopharma clients’ biomarker discovery and clinical trial projects.   The addition of the NovaSeq’s powerful processing capabilities to Almac’s existing range of NGS platform offerings will allow for larger sample runs, greater read depth, and faster speeds. The new instrument will also ultimately reduce sample turnaround times and increase variant detection qualit...